In this report, the Global Endocrine Testing Market has been segmented by Test, Indication, Technology, End Use and Geography.

Global Endocrine Testing Market, Segmentation by Test

The Global Endocrine Testing Market has been segmented by Test into Thyroid Test, Insulin Test, Human Chorionic Gonadotropin Test, Prolactin Test, Luteinizing Hormone Test, Progesterone Test, and Others.

Thyroid Test
Thyroid tests dominate the global endocrine testing market, holding approximately 30% share. These include TSH, free T3, and free T4 assays, which are crucial for identifying thyroid dysfunctions such as hypothyroidism and hyperthyroidism. With rising global awareness, especially among women and aging populations, demand for routine thyroid screening continues to grow.

Insulin Test
Insulin tests account for nearly 20% of the market and are essential for evaluating glucose metabolism, identifying insulin resistance, and monitoring diabetes management. As the global diabetes burden surges, especially in urban populations, the importance of regular insulin profiling has grown significantly.

Human Chorionic Gonadotropin (hCG) Test
hCG testing represents about 15% of the market and remains the most commonly used method for pregnancy confirmation. Additionally, it plays a role in diagnosing trophoblastic tumors and monitoring certain cancers. The widespread use of hCG testing in obstetrics and gynecology clinics sustains its relevance.

Prolactin Test
Prolactin tests make up around 10% of the market and are key for evaluating pituitary adenomas, infertility, and galactorrhea. As reproductive health becomes a growing concern globally, especially among women of childbearing age, the use of prolactin assays is on the rise.

Luteinizing Hormone Test
Luteinizing hormone (LH) testing, with about 8% share, plays a pivotal role in the diagnosis of ovulation disorders, menstrual irregularities, and pituitary abnormalities. The growing trend in fertility treatments and hormonal therapy is boosting adoption.

Progesterone Test
Progesterone tests, accounting for roughly 7%, are used to assess ovulatory function, monitor pregnancy progression, and guide hormonal therapies. Their relevance is growing with the expansion of assisted reproductive technologies (ART) and prenatal care programs.

Others
The Others segment (~10%) encompasses a wide range of hormone tests, including testosterone, cortisol, estradiol, and ACTH. These are vital for diagnosing conditions like adrenal insufficiency, Cushing’s syndrome, and hormonal imbalances in men and women alike.

Global Endocrine Testing Market, Segmentation by Indication

The Global Endocrine Testing Market has been segmented by Indication into Addison's Disease, Cushing's Disease, Diabetes, Graves' Disease, and Hashimoto Thyroiditis.

Addison's Disease
Addison’s disease makes up about 10% of the endocrine testing market. Testing typically includes serum cortisol, ACTH stimulation tests, and aldosterone assays to confirm adrenal gland dysfunction. Though a rare condition, increasing awareness and better screening protocols are prompting earlier diagnosis and management, especially in patients with autoimmune comorbidities.

Cushing's Disease
Cushing’s disease holds approximately 14% of the market. It involves the overproduction of cortisol, and diagnosis requires tests like 24-hour urinary cortisol, late-night salivary cortisol, and dexamethasone suppression tests. The condition’s growing link with metabolic disorders is pushing greater use of cortisol-focused endocrine panels.

Diabetes
Diabetes dominates the indication-based segmentation with an estimated 48% share. Diagnostic testing includes insulin, HbA1c, and C-peptide evaluations, all critical for both diagnosis and ongoing disease management. The increasing global incidence of type 2 diabetes is driving routine testing across primary care, endocrinology clinics, and diagnostic labs.

Graves' Disease
Graves’ disease contributes nearly 16% of the market. Characterized by autoimmune hyperthyroidism, it is diagnosed using TSH, free T4, and TSI antibody tests. With growing cases of thyroid-related eye complications and heart rhythm disturbances, the demand for early thyroid autoimmunity testing is increasing.

Hashimoto Thyroiditis
Hashimoto thyroiditis holds a market share of about 12%. It is the most common cause of hypothyroidism, particularly in middle-aged women. Testing typically includes TSH, TPO antibodies, and thyroid hormone levels to monitor autoimmune thyroid function. Rising public health campaigns around thyroid health awareness support ongoing demand.

Global Endocrine Testing Market, Segmentation by Technology

The Global Endocrine Testing Market has been segmented by Technology into Immunoassay, Tandem Mass Spectroscopy, Sensor Technology, and Others.

Immunoassay
Immunoassay is the leading technology in endocrine testing, holding around 55% of the global market. It is extensively used for evaluating thyroid function, reproductive hormones, and insulin levels. The technology’s affordability, automation compatibility, and rapid turnaround time make it the first choice for high-volume diagnostic laboratories worldwide.

Tandem Mass Spectroscopy
Tandem mass spectroscopy (MS/MS) accounts for roughly 25% of the market. Its high specificity, low detection limits, and ability to differentiate structurally similar hormones make it ideal for testing complex endocrine profiles, including cortisol, testosterone, and vitamin D metabolites. Its use is expanding across advanced reference labs and academic research centers.

Sensor Technology
Sensor technology, representing about 12% of the market, includes a range of biosensors, electrochemical sensors, and wearable diagnostics that enable continuous hormone monitoring, especially for glucose and insulin. The growth of remote patient monitoring, digital health platforms, and non-invasive diagnostics is accelerating adoption in both clinical and consumer wellness spaces.

Others
The Others segment (~8%) includes traditional technologies like radioimmunoassay, spectrophotometry, and chromatographic techniques. While their usage is declining in mainstream diagnostics, they remain essential in low-resource settings, academic studies, and historical data comparisons for hormonal trends.

Global Endocrine Testing Market, Segmentation by End User

The Global Endocrine Testing Market has been segmented by End User into Hospitals, Clinical Laboratories, and Others.

Hospitals
Hospitals lead the global endocrine testing market, accounting for approximately 48% of the total share. Their comprehensive infrastructure allows for in-house hormone testing, particularly for conditions like thyroid dysfunction, diabetes, and reproductive disorders. Equipped with automated analyzers and integrated lab services, hospitals are preferred for both emergency diagnostic evaluations and routine hormone panels, especially in multispecialty and tertiary care centers.

Clinical Laboratories
Clinical laboratories make up about 42% of the market and play a central role in outpatient hormone diagnostics. These facilities offer cost-efficient, high-throughput endocrine testing and are often the first point of contact for routine thyroid panels, HbA1c, and fertility hormone tests. The expansion of home testing kits, sample pickup services, and online reporting is further fueling demand for lab-based services.

Others
The Others segment (~10%) includes research institutions, public health centers, and mobile diagnostic units involved in endocrine testing. These entities are vital for clinical studies, rural outreach programs, and point-of-care testing, particularly in resource-constrained settings or for specialized hormone assays used in medical research and pilot projects.

Global Endocrine Testing Market, Segmentation by Geography

In this report, the Global Endocrine Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Global Endocrine Testing Market Share (%), by Geographical Region, 2024

North America
North America dominates the global endocrine testing market with an estimated 38% share. The region’s leadership is driven by widespread use of automated hormone analyzers, strong insurance coverage, and a high burden of chronic endocrine conditions such as diabetes, hypothyroidism, and polycystic ovary syndrome (PCOS). The U.S. is the primary contributor, with advanced diagnostic networks and frequent adoption of personalized testing protocols.

Europe
Europe holds about 27% of the market, supported by strong government healthcare systems and increasing emphasis on preventive diagnostics. With a rapidly aging population and high public awareness of hormonal disorders, countries like Germany, France, and the UK are investing in early detection technologies, particularly for thyroid and reproductive health.

Asia Pacific
Asia Pacific commands roughly 24% of the market and is witnessing the highest growth rate. The region is seeing a surge in endocrine diseases, especially type 2 diabetes, as a result of urban lifestyle changes and dietary shifts. Governments across India, China, and Southeast Asia are expanding diagnostic access through public funding and private sector collaboration.

Middle East & Africa
Middle East & Africa make up approximately 6% of the global market. Countries like Saudi Arabia, UAE, and South Africa are enhancing their healthcare delivery models, focusing on screening for metabolic and thyroid disorders. Increased support for non-communicable disease management and international partnerships is helping address diagnostic gaps.

Latin America
Latin America accounts for nearly 5% of the market, driven by rising demand for diabetes and fertility hormone testing. Brazil and Mexico lead the region’s diagnostic evolution with efforts to boost healthcare accessibility, telehealth programs, and awareness campaigns on endocrine health.